New patent for Sanofi Aventis drug APIDRA

Annual Drug Patent Expirations for APIDRA
Annual Drug Patent Expirations for APIDRA

Apidra is a drug marketed by Sanofi Aventis Us
and is included in one NDA. It is available from one supplier. There are thirteen patents protecting this drug.

This drug has eigthy patent family members in thirty-nine countries.

The generic ingredient in APIDRA is insulin glulisine recombinant. One supplier is listed for this compound. Additional details are available on the insulin glulisine recombinant profile page.

For more information on how DrugPatentWatch can help with your pharmaceutical business intelligence needs,
contact admin@DrugPatentWatch.com
or visit www.DrugPatentWatch.com